KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Gains from Investment Securities (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Gains from Investment Securities readings, the most recent being -$1.0 million for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 385.11% to -$1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $550000.0, a 67.72% decrease, with the full-year FY2025 number at $550000.0, down 67.72% from a year prior.
  • Gains from Investment Securities hit -$1.0 million in Q4 2025 for Biocryst Pharmaceuticals, down from $513000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $25.1 million in Q2 2021 to a low of -$1.6 million in Q2 2024.
  • Median Gains from Investment Securities over the past 5 years was $546000.0 (2024), compared with a mean of $2.6 million.
  • Biggest five-year swings in Gains from Investment Securities: surged 3490.32% in 2021 and later tumbled 385.11% in 2025.
  • Biocryst Pharmaceuticals' Gains from Investment Securities stood at $900000.0 in 2021, then tumbled by 56.56% to $391000.0 in 2022, then soared by 455.5% to $2.2 million in 2023, then plummeted by 83.61% to $356000.0 in 2024, then crashed by 385.11% to -$1.0 million in 2025.
  • The last three reported values for Gains from Investment Securities were -$1.0 million (Q4 2025), $513000.0 (Q3 2025), and $536000.0 (Q2 2025) per Business Quant data.